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BACKGROUND Due to deliverability and thrombogenicity concerns,
efforts are being made to decrease the strut thickness of the bio-
resorbable stents without compromising radial strength and dura-
bility. This study aimed to evaluate the scaffold expansion of the
novel sirolimus-eluting scaffolds with 120mm and 150mm strut thick-
ness (AMA-120 or -150, Amaranth Medical, Mountain View, CA),
compared to Absorb BVS using previously described (TCT2014)
methods.
METHODS A total of 125 scaffolds (32 AMA-120; 46 AMA-150 and 47
Absorb) were implanted (stent-to-artery ratio: 1.1:1) in coronary ar-
teries of 51 healthy swine. Angiography and OCT imaging were per-
formed at post-implant, 28-day and 90-day follow up. Minimum
balloon diameter (MBD) of the last inﬂated balloon at the highest
pressure and minimum stent diameter (MSD) immediately after the
last balloon deﬂation were assessed by QCA. % Acute Recoil (AR) was
deﬁned as (MBD-MSD)/MBDx100%. Projected Diameter (PD) was
deﬁned as the stent diameter to be achieved per compliance chart at
the pressure used. Accordingly, % Under-expansion (in vivo stent
response to arterial elastic forces regardless of “native” recoil) was
deﬁned as (PD-MBD)/PDx100%. Total Stent Deﬁcit is the sum of the %
under-expansion and % AR ¼ (PD-MSD)/PDx100% (FIGURE). Addi-
tionally, % Late Recoil (LR) was examined by OCT and deﬁned as
(inner scaffold area at post-procedure – inner scaffold area at follow-
up)/ inner scaffold area at post-procedure.
RESULTS The results are summarized in the TABLE. There was no
signiﬁcant difference in % AR between AMA-120, AMA-150 and
Absorb. %Under-expansion of AMA-150 was slightly higher than
AMA-120 and similar to Absorb. Consequently, Total Stent Deﬁcit
showed the same trend as the under-expansion. The % LR in AMA
BVS groups was less or similar to that in Absorb BVS at 28 days and 90
days.AMA 120 AMA 150 Absorb BVS P ValueQCA %ACUTE RECOIL 1%8% 2%8% 3%7% 0.32%UNDERXPANSION 2%7% 6%7% 7%9% 0.04
TOTAL STENT
DEFICIT3%8% 8%9% 10%7% 0.001OCT % Late Recoil (DAY
28)-2%8% 3%4% 7%7% 0.02% Late Recoil (DAY
90)-1%7% -5%15% 3%11% 0.17CONCLUSIONS The novel 120mm sirolimus-eluting bioresorbable
scaffold demonstrated acute and chronic radial strength in vivo
equivalent or better than its regular-thickness counterpart or Absorb
BVS.
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BACKGROUND Long-term follow-up of bioresorbable scaffolds evi-
denced vascular dimensional restoration, in contrast to the vascular
caging characteristic in permanent metallic stents (BMS). We aim to
evaluate the chronic, in vivo, vascular changes following the coronary
implantation of a novel non-drug eluting, magnesium-based, bio-
resorbable scaffold (MBRS).
METHODS Six stents (MBRS¼3 vs BMS¼3) were implanted (1.1:1 B:A
ratio by angiography) in RCA of juvenile swine and evaluated by OCT
at baseline, 1, 2 and 3 months. Morphometry was assessed at every
time point in stented and reference segments.
RESULTS The non-stented reference segments demonstrated a pro-
gressive increase in lumen area (1 month¼8.01.0mm2, 2
months¼10.52.0 mm2, 3 months¼10.71.9 mm2) that was aligned
with the mean growth of the animal (1 month¼ 39kg, 2 months¼
47kgs, 3 months¼ 58kgs). As expected, there was no geometrical
changes in the BMS stents. BMS did not display modiﬁcations in their
stent area (6.00.3 mm2, at each time point) or lumen area (1 and 2
months¼5.60.4mm2, 3 months¼ 6.00.6 mm2) with a consistent
neointimal obstruction (1 and 2 months¼0.10.1%, 3 month-
s¼0.00.1%). In contrast, MBRS showed a gradually progressive in-
crease in stent area from 1 month (5.80.5 mm2) to a >30% increase at
3 months (7.62.2 mm2) and an additional 30% at 3 months
(10.32.5 mm2). Importantly is to note that at three month the stent
area in MBRS (10.32.5 mm2) is exactly the same as the reference
segment (10.71.9 mm2). In parallel, the luminal area increase
accordingly (1 month¼4.40.6 mm2, 2 months¼6.52.1, 3
months¼8.21.5 mm2). The neointimal obstruction observed in MBRS
remained constantly minimal (1 month¼0.20.1%, 2 month-
s¼0.20.0%, 3 months¼0.20.1%).
CONCLUSIONS In this preliminary experimental study, the novel
bare magnesium-based bioresorbable stent was associated with
dimensional restoration and vascular adaptability to remodel outward
to match the physiological and dimension requirements of the coro-
nary artery without excessive neointimal proliferation in contrast
with the encaged coronary treated with BMS.
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BACKGROUND The safety and efﬁcacy of the Absorb (Abbott) bio-
resorbable vascular scaffold (BVS) has been documented in lower-risk
patient and lesion subsets with “real-world” outcome data being
scarce. Here we report the experience gathered with the BVS primarily
in daily practice at a high-volume Dutch center.
METHODS Between July 2009 – January 2015, 297 patients (330 le-
sions) were treated with BVS. Registry data collection is ongoing and
gathered prospectively in-hospital, at 1 and 6 months and then yearly
up to 5 years.
RESULTS Mean follow-up time was 323 days (median 236 days) with
44% of patients having at least 1 year of follow-up. Clinical presen-
tation of pts. (73% male, mean age 59 years, 16% diabetes, 25% with
previous PCI and/or CABG) was ACS in 55%. Lesion complexity was
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B219B2/C in 56.6% with mean lesion length by QCA of 24.1 mm with a mean
RVD of 2.6 mm and a mean lumen obstruction of 66.1%. Pre-dilatation
was performed in 94% and post-dilatation in 59%. The mean scaffold
length was 27.4 mm with 36% of cases using 2 stents and 26% of
cases using overlapping scaffolds. OCT or IVUS was used in 30%.
Device success was 98.0% (failure to expand in 1 pts. and deliver in 5
pts.). Over the entire follow-up period, death occurred in 1.7% (5/297),
myocardial infarction (MI) in 2.7% (total of 8 cases, 1 of peri-proce-
dural), target lesion revascularization in 3.4%, target vessel revascu-
larization (TVR) in 4.7%, non-target vessel revascularization 1.3%.
Deﬁnite stent thrombosis (ST) occurred in 6 pts. (2.0%) and probable
ST in 1 pt. (0.3%); all ST were early including one acute ST except of
two case of deﬁnite ST which occurred at days 40 and 84, respec-
tively. Overall MACE (death, MI, TVR) rate was 6.4% (19/297).
CONCLUSIONS This registry including patients with ACS and com-
plex lesion characteristics documents a good safety and efﬁcacy pro-
ﬁle of the BVS. However, stent thrombosis rates in particular early
after BVS implantation have to be closely monitored. More data
including complex patient and lesion subsets as well as longer follow-
ups are needed to deﬁne the role of BVS in daily practice.
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BACKGROUND Tissue formation at coronary bifurcations is related to
vascular endothelial shear stress, and postmortem pathological
studies have described different patterns of neointimal coverage be-
tween the outer wall and inner wall at coronary bifurcations treated
with ﬁrst-generation drug-eluting stents (DES). Current everolimus-
eluting bioresorbable scaffolds (BRS) have thicker struts compared to
their metallic counterparts, and could therefore have a stronger in-
ﬂuence on vascular endothelial shear stress compared to DES. How-
ever, the neointimal coverage of bifurcation lesions treated with BRS
has not been adequately studied. In the current study, we sought to
evaluate the vascular response to BRS struts deployed at bifurcation
segments using optical coherence tomography (OCT).
METHODS This study included 37 patients (51 bifurcation lesions)
examined with coronary angiography including OCT 11.0  2.1 months
after BRS implantation. Cross-sectional area (CSA) of the bifurcation
lesion with a side branch more than 1mm using OCT were analyzed
every 200mm. All images were divided into 3 regions according to the
shear stress: one half of the circumference of the vessel opposite to
the ostium (OO), the side branch ostium (SO), and the vessel wall
adjacent to the ostium (AO). All struts in OO, AO, and SO regions were
classiﬁed as covered or uncovered. The thickness of coverage was
measured in each CSA, and the averaged neointimal thickness (NIT)
was calculated. Additionally, to evaluate the impact of the side branch
size on neointimal proliferation, we classiﬁed side branches according
to the ratio of the diameter of the side branch ostium (Ds) to the
diameter of main branch (Dm).
RESULTS The mean age of the study population was 5711 years.
Mean BRS diameter and length were 3.10.37 and 21.05.7mm,
respectively. The mean diameter of all side branches was
1.590.55mm. Overall, there was a signiﬁcant difference in NIT among
the 3 examined regions (OO, 11968 vs. AO, 9435 vs. SO, 8041mm,
p¼0.03). In addition, a signiﬁcant difference was observed in the
percentage of uncovered struts among the 3 regions (OO, 0.43 vs. AO,
1.4 vs. SO, 4.8%, p¼0.02). Lesions were divided into 2 groups based on
a median value of Ds/Dm of 0.318 (large ratio side branch group ¼
LRSB, n¼26; and small ratio side branch group ¼ SRSB, n¼25). In the
LRSB group, there was a signiﬁcant difference in NIT (OO, 12861 vs.
AO, 913.6 vs. SO, 7438 mm, p¼0.01) and in the percentage of un-
covered struts (OO, 0.38 vs. AO, 2.0 vs. SO, 8.7%, p¼0.01) between the
3 regions, but this was not observed in the SRSB group.
CONCLUSIONS Different patterns of neointimal coverage are
observed between the outer wall and inner wall of coronary bifurca-
tion lesions treated with everolimus-eluting BRS. Neointimal
coverage is least at and adjacent to large side branches.CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
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BACKGROUND Degradation of bioresorbable stents (BRS) has been
shown to allow restoration of the treated segment’s plasticity and
reactivity to those resembling a non-stented artery, a desirable feature
unattainable with metallic stents (BMS). We have previously reported
the dynamic changes in arterial geometry in response to a novel non-
drug eluting BRS as compared to BMS up to 2 years. This study pro-
vides an insight over a 3-year duration.
METHODS Forty-seven coronary arteries of 19 swine received BRS
(Amaranth Medical, Mountain View, CA n¼34) or BMS (Liberte Bos-
ton Scientiﬁc, Natick, MA n¼13). Optical coherence tomography (OCT)
was done at day 0, 1 month (BRS, n¼26; BMS, n¼13), 1 year (BRS, n¼12;
BMS, n¼4), 2 years (BRS, n¼13; BMS, n¼4) and 3 years post implant
(BRS, n¼11; BMS, n¼3).
RESULTS The lumen areas of reference segments increased over time in
both BMS-caged segments (Day 0¼6.091.80mm2, 2 Years¼10.55
2.95mm2 and 3 Years¼13.583.23mm2, p<0.05) and the BAS-treated
arteries (Day 0¼6.631.21mm2, 2 Years¼11.632.30mm2 and 3
Years¼12.162.72mm2,p<0.05).BMSshowed lumenarea loss at 1monthas
expected due to neointimal formation, and then minimal lumen area
variance over time up to 3 years (Day 0¼6.791.7mm2, 2
Years¼6.782.25mm2, and3years¼7.371.83mm2,p>0.05). In contrast, in
BAS the early lumen area loss present at 1 month inverted into lumen gain
that corresponded with the scaffold expansion as it degraded, paralleling
the artery growth (scaffold area, Day 0¼6.871.17mm2, 2
Years¼11.661.51mm2, and 3 years¼13.872.75 mm2, p<0.05) and allow-
ing the treated segment to remodel (lumen area, Day 0¼6.871.17mm2, 2
Years¼9.671.56mm2, and 3 years¼11.942.77mm2, p<0.05, Figure). %
Area Stenosis did not show signiﬁcant difference between BMS and BRS
over time.
CONCLUSIONS Between 2 and 3 years after implantation, BRS treated
coronary artery segments continue to positively remodel, with further
late lumen area gain paralleling the reference segment expansion over
time. This pattern, uniquely possible due to scaffold degradation and
unattainable in the BMS-caged segments, appears to be a reproducible
and inherent behavior of non-drug eluting bioresorbable stents in the
normal porcine coronary model.
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